Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cerolizumab pegol

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Research Partnership

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Janssen shares new clinical trial data on its psoriasis treatment Tremfya

The results were presented at the 2022 AAD Annual Meeting in March

- PMLiVE

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

Avalere Health

Parallel HCP-Patient Advisory Boards: A Customer Story

Learn how a Pharma team engaged both dermatologists and patients with psoriasis in two parallel virtual advisory boards.

Impetus Digital

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

UCB boosts gene therapy offering with a pair of new deals

Company will collaborate with Lacerta Therapeutics and acquire Handl Therapeutics

- PMLiVE

Fishawack Health launches global ‘PsoriasIS NOT CONTAGIOUS’ mask campaign for World Psoriasis Day 2020

Fishawack Health launches global disease awareness campaign, supported by the community of Psoriasis Warriors to de-stigmatize psoriasis during the COVID-19 pandemic.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links